(IN BRIEF) Sanofi has boosted its venture capital arm, Sanofi Ventures, with a new $625 million multi-year commitment, raising the fund’s assets under management to more than $1.4 billion. Since 2012, Sanofi Ventures has invested over $800 million in more … Read the full press release
Posted in France, Healthcare, Pharma & Biotech
Tagged AI in healthcare, Biotech, digital health, early-stage funding, Healthcare Innovation, immunology, IPOs, Jason P Hafler, medical breakthroughs, Neurology, Paul Hudson, rare diseases, Sanofi, Sanofi boosts its venture arm with fresh $625 million funding to support biotech and digital health startups, Sanofi expands Sanofi Ventures with $625 million to drive biotech and digital health breakthroughs, Sanofi Ventures, scientific progress, vaccines, venture capital
(IN BRIEF) Sanofi has finalized its takeover of Vigil Neuroscience for roughly $470 million, acquiring all outstanding shares at $8 each and issuing a $2-per-share CVR tied to VG-3927’s first commercial sale. This deal, following Sanofi’s June 2024 strategic investment, … Read the full press release
Posted in Business, Financial, France, Government, Healthcare, Industrial, Investment, Management, Marketing, News, Pharma & Biotech, Science, Technology
Tagged acquisition, Alzheimer’s disease, contingent value right, CVR, neurodegenerative research, Neurology, partnership, Phase 2 clinical study, preclinical pipeline, Sanofi, strategic investment, TREM2 agonist, VG-3927, VGL101, Vigil Neuroscience
(IN BRIEF) Merck, a prominent science and technology company, has announced strategic drug discovery collaborations with AI technology firms BenevolentAI and Exscientia. These partnerships aim to leverage AI-driven design and discovery capabilities to advance research efforts in key therapeutic areas, … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Germany, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged AI, AI-Driven Drug, BenevolentAI, Danny Bar-Zohar, data, Exscientia, immunology, Merck, Neurology, oncology, partnership, science
(IN BRIEF) H. Lundbeck A/S has announced the initiation of CEO succession, with Deborah Dunsire choosing to retire from her role as President and CEO. Charl van Zyl has been appointed as the new President and CEO, and Dunsire will … Read the full press release
Posted in Business, Denmark, Healthcare, Management, Pharma & Biotech
Tagged appointment, biopharma, Board of Directors, CEO, Charl van Zyl, CNS, Deborah Dunsire, Eli Lilly, H. Lundbeck A/S, immunology, Lars Rasmussen, Lundbeck, Neurology, Novartis
(PRESS RELEASE) LIVERPOOL, 16-Oct-2020 — /EuropaWire/ — A new global project has been established to better understand how and why COVID-19 affects the brain. The COVID-Neuro Global programme, led by the University of Liverpool in cooperation with five leading research … Read the full press release
Posted in Education, Healthcare, News, Science, Society, United Kingdom
Tagged brain infections, Christian Medical College Vellore, COVID-19, COVID-Neuro Global programme, Dr Ava Easton, Faculty of Health and Life Sciences, infectious diseases, Institute of Infection Veterinary and Ecological Sciences, Malawi-Liverpool-Wellcome Trust Clinical Research Programme, National Institute for Health Research, National Institute for Mental Health & Neuro Sciences, Neurology, NIHR, NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Oswaldo Cruz Foundation, Professor Ravi Vasanthapuram, Professor Tom Solomon, The College of Medicine, The Encephalitis Society, UK Research and Innovation, UKRI, University of Liverpool
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?